Table 1. Clinical and pathological... | American Society of Hematology

Table 1.

Clinical and pathological features of MLBCL and DLBCL patients and tumors

Clinical feature	MLBCL, n = 34	DLBCL, n = 176
Median age, y (range)	32 (14-59)	64 (20-92)
Sex (%)
Female	24 (71)	84 (48)
Male	10 (29)	92 (52)
Stage (%)
I/II	25 (74)	53 (30)
III/IV	9 (26)	115 (65)
Unknown	0 (0)	8 (5)
Pathology (%)		N/A
Sclerosis
Present	32 (94)
Absent	2 (6)
Immunoglobulin by IHC^*
Present	3 (12)
Absent	20 (77)
Equivocal	3 (12)
Not available	8
FISH†		N/A‡
BCL2 rearrangements	0
BCL6 rearrangements	1

Clinical feature	MLBCL, n = 34	DLBCL, n = 176
Median age, y (range)	32 (14-59)	64 (20-92)
Sex (%)
Female	24 (71)	84 (48)
Male	10 (29)	92 (52)
Stage (%)
I/II	25 (74)	53 (30)
III/IV	9 (26)	115 (65)
Unknown	0 (0)	8 (5)
Pathology (%)		N/A
Sclerosis
Present	32 (94)
Absent	2 (6)
Immunoglobulin by IHC^*
Present	3 (12)
Absent	20 (77)
Equivocal	3 (12)
Not available	8
FISH†		N/A‡
BCL2 rearrangements	0
BCL6 rearrangements	1

N/A indicates not available.

MLBCL immunoglobulin status by immunohistochemistry (IHC) available for 26 patients (% positive calculated on available cases)

MLBCL interphase FISH available: BCL2, 17 patients; BCL6, 19 patients

To be described in a subsequent analysis